Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

681. Curative ablation for atrial fibrillation: a systematic review

Curative ablation for atrial fibrillation: a systematic review Curative ablation for atrial fibrillation: a systematic review Curative ablation for atrial fibrillation: a systematic review Gjesdal K, Vist G E, Bugge E, Rossvoll O, Johansen M, Norderhaug I, Ohm O J CRD summary This systematic review concluded that catheter ablation was more effective than drug therapy for atrial fibrillation, but that data on adverse effects was sparse. The review appeared to have been reasonably well conducted (...) , although poor reporting limited the assessment of some sources of bias. The authors' conclusions reflected the evidence presented, but the low quality of the included studies limited the reliability of the conclusions. Authors' objectives To assess the effectiveness of catheter ablation for atrial fibrillation. Searching MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, The Cochrane Library, meta Register of Controlled Trials and relevant websites were searched to May 2007. Study

DARE.2008

682. Patients with lone atrial fibrillation had low risk of progression to permanent atrial fibrillation, death, congestive heart failure, and stroke

Patients with lone atrial fibrillation had low risk of progression to permanent atrial fibrillation, death, congestive heart failure, and stroke Patients with lone atrial fibrillation had low risk of progression to permanent atrial fibrillation, death, congestive heart failure, and stroke | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients with lone atrial fibrillation had low risk of progression to permanent atrial fibrillation, death, congestive heart failure, and stroke Article Text Prognosis Patients with lone atrial fibrillation had low

Evidence-Based Medicine (Requires free registration)2008

683. Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation

Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation Article Text This article has a correction. Please see: Diagnosis Accuracy of ECG interpretation in primary care was limited for detecting atrial fibrillation Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2008

684. Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation

Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation Article Text Therapeutics Systematic or opportunistic screening was more effective than usual care for detecting new cases of atrial fibrillation Statistics

Evidence-Based Medicine (Requires free registration)2008

685. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W)

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) 18323500 2008 04 29 2008 05 29 2016 11 24 1524-4628 39 5 2008 May Stroke Stroke Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation (...) clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). 1482-6 10.1161/STROKEAHA.107.500199 In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk stratification schemes have been devised to identify patients for whom the absolute benefits of OAC exceed its risks. Participants were risk-stratified

EvidenceUpdates2008

686. Relation of Recurrence of Atrial Fibrillation After Non-ST-Elevation Acute Myocardial Infarction to Left Atrial Abnormality

Relation of Recurrence of Atrial Fibrillation After Non-ST-Elevation Acute Myocardial Infarction to Left Atrial Abnormality 18157961 2007 12 25 2008 02 06 2016 11 24 0002-9149 101 1 2008 Jan 01 The American journal of cardiology Am. J. Cardiol. Relation of recurrence of atrial fibrillation after non-ST-elevation acute myocardial infarction to left atrial abnormality. 30-4 Atrial fibrillation (AF) is common during the course of acute myocardial infarction and is associated with left atrial (LA (...) ) dilatation. However, the role of LA depolarization abnormality on the electrocardiogram (ECG) in the setting of LA dilatation was not studied in this context. Patients admitted with non-ST-segment elevation myocardial infarction (NSTEMI) who developed new-onset AF (International Classification of Diseases, Ninth Revision code 427.31) were prospectively identified. Baseline ECGs and echocardiograms before the admission event were reviewed. Follow-up was directed toward pertinent cardiovascular events

EvidenceUpdates2008

687. Rhythm control versus rate control for atrial fibrillation and heart failure.

Rhythm control versus rate control for atrial fibrillation and heart failure. 18565859 2008 06 20 2008 06 26 2016 08 03 1533-4406 358 25 2008 Jun 19 The New England journal of medicine N. Engl. J. Med. Rhythm control versus rate control for atrial fibrillation and heart failure. 2667-77 10.1056/NEJMoa0708789 It is common practice to restore and maintain sinus rhythm in patients with atrial fibrillation and heart failure. This approach is based in part on data indicating that atrial fibrillation (...) is a predictor of death in patients with heart failure and suggesting that the suppression of atrial fibrillation may favorably affect the outcome. However, the benefits and risks of this approach have not been adequately studied. We conducted a multicenter, randomized trial comparing the maintenance of sinus rhythm (rhythm control) with control of the ventricular rate (rate control) in patients with a left ventricular ejection fraction of 35% or less, symptoms of congestive heart failure, and a history

NEJM2008

688. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. 18294998 2008 02 25 2008 03 10 2015 06 16 1474-547X 371 9609 2008 Jan 26 Lancet (London, England) Lancet Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. 315-21 10.1016/S0140-6736(08)60168-3 Vitamin K (...) antagonists, the current standard treatment for prophylaxis against stroke and systemic embolism in patients with atrial fibrillation, require regular monitoring and dose adjustment; an unmonitored, fixed-dose anticoagulant regimen would be preferable. The aim of this randomised, open-label non-inferiority trial was to compare the efficacy and safety of idraparinux with vitamin K antagonists. Patients with atrial fibrillation at risk for thromboembolism were randomly assigned to receive either

Lancet2008

689. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial.

Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. 18854540 2008 10 15 2008 10 20 2016 10 17 1538-3598 300 15 2008 Oct 15 JAMA JAMA Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. 1784-92 10.1001/jama.300.15.1784 Amiodarone effectively suppresses atrial fibrillation but causes many adverse events. To compare major events in patients randomized (...) to receive episodic amiodarone treatment with those who received continuous amiodarone treatment while still aiming to prevent atrial fibrillation. A randomized trial of 209 ambulatory patients with recurrent symptomatic persistent atrial fibrillation, conducted from December 2002 through March 2007 at 7 Dutch medical centers. Patients were randomly assigned to receive either episodic or continuous amiodarone treatment after electrical cardioversion following amiodarone loading. Episodic amiodarone

JAMA2008

690. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure.

Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. 18946063 2008 10 23 2008 10 30 2008 10 23 1533-4406 359 17 2008 Oct 23 The New England journal of medicine N. Engl. J. Med. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. 1778-85 10.1056/NEJMoa0708234 Pulmonary-vein isolation is increasingly being used to treat atrial fibrillation in patients with heart failure. In this prospective, multicenter clinical trial, we randomly assigned (...) patients with symptomatic, drug-resistant atrial fibrillation, an ejection fraction of 40% or less, and New York Heart Association class II or III heart failure to undergo either pulmonary-vein isolation or atrioventricular-node ablation with biventricular pacing. All patients completed the Minnesota Living with Heart Failure questionnaire (scores range from 0 to 105, with a higher score indicating a worse quality of life) and underwent echocardiography and a 6-minute walk test (the composite primary

NEJM2008

691. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. BACKGROUND: Atrial fibrillation (AF) is the most frequent sustained arrhythmia. After restoration of normal sinus rhythm, the recurrence rate of AF is high. Antiarrhythmic drugs have been widely used to prevent recurrence, but the effect of these drugs on mortality and other clinical outcomes is unclear. OBJECTIVES: To determine, in patients who recovered sinus rhythm after AF, the effect of long-term (...) treatment with antiarrhythmic drugs on death, stroke and embolism, adverse effects, pro-arrhythmia and recurrence of AF. If several antiarrhythmics were effective our secondary aim was to compare them. SEARCH STRATEGY: The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Libary (Issue 2, 2005), MEDLINE (1950 to May 2005) and EMBASE (1966 to May 2005) were searched. The reference lists of retrieved articles, recent reviews and meta-analyses were checked. No language restrictions

Cochrane2007

692. Management of atrial fibrillation.

Management of atrial fibrillation. Atrial fibrillation is the most common sustained cardiac rhythm disorder, and confers a substantial mortality and morbidity from stroke, thromboembolism, heart failure, and impaired quality of life. With the increasingly elderly population in the developed world, as well as improvements in the management of myocardial infarction and heart failure, the prevalence of atrial fibrillation is increasing, resulting in a major public-health problem. This Review aims (...) to provide an overview on the modern management of atrial fibrillation, with particular emphasis on pharmacological and non-pharmacological approaches. Irrespective of a rate-control or rhythm-control strategy, stroke prevention with appropriate thromboprophylaxis still remains central to the management of this common arrhythmia. Electrophysiological approaches could hold some promise for a curative approach in atrial fibrillation.

Lancet2007

693. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. BACKGROUND: Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use. OBJECTIVES: To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated (...) for prevention of thromboembolism in AF. SEARCH STRATEGY: Articles were identified through the Cochrane Collaboration's CENTRAL database and MEDLINE until December 1999. SELECTION CRITERIA: Included Randomized controlled trials of drugs to prevent thromboembolism in adults with non-postoperative AF. Excluded RCTS of patients with rheumatic valvular disease. DATA COLLECTION AND ANALYSIS: Data were abstracted by two reviewers. Odds ratios from all qualitatively similar studies were combined, with weighting

Cochrane2007

694. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.

Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. BACKGROUND: Non-valvular atrial fibrillation (AF) carries an increased risk of stroke mediated by embolism of stasis-precipitated thrombi originating in the left atrial appendage. Both oral anticoagulants and antiplatelet agents have proven effective for stroke prevention in most patients at high risk for vascular events (...) , but primary stroke prevention in patients with non-valvular AF potentially merits separate consideration because of the suspected cardio-embolic mechanism of most strokes in AF patients. OBJECTIVES: To characterize the relative effect of long-term oral anticoagulant treatment compared with antiplatelet therapy on major vascular events in patients with non-valvular AF and no history of stroke or transient ischemic attack (TIA). SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (June

Cochrane2007

695. Negative D-dimer may allow safe early cardioversion of atrial fibrillation

Negative D-dimer may allow safe early cardioversion of atrial fibrillation BestBets: Negative D-dimer may allow safe early cardioversion of atrial fibrillation Negative D-dimer may allow safe early cardioversion of atrial fibrillation Report By: Richard Body - Specialist Registrar Search checked by Babak Allie - Specialist Registrar Institution: Manchester Royal Infirmary Date Submitted: 30th August 2005 Date Completed: 29th May 2007 Last Modified: 19th April 2007 Status: Green (complete) Three (...) Part Question In [patients with atrial fibrillation being considered for electrical or pharmacologic cardioversion] does [measurement of D-dimer] allow [exclusion of atrial thrombus]? Clinical Scenario A 45 year-old man presents to the Emergency Department with a 48-hour history of palpitations, postural light-headedness and exertional dyspnoea. ECG demonstrates atrial fibrillation (AF) at a rate of 130 beats/minute. There are no apparent reversible causes following history, examination, chest

BestBETS2007

696. Pulse pressure and risk of new-onset atrial fibrillation.

Pulse pressure and risk of new-onset atrial fibrillation. CONTEXT: Atrial fibrillation (AF) is responsible for considerable morbidity and mortality, making identification of modifiable risk factors a priority. Increased pulse pressure, a reflection of aortic stiffness, increases cardiac load and may increase AF risk. OBJECTIVE: To examine relations between pulse pressure and incident AF. DESIGN, SETTING, AND PARTICIPANTS: Prospective, community-based observational cohort in Framingham, Mass (...) , including 5331 Framingham Heart Study participants aged 35 years and older and initially free from AF (median age, 57 years; 55% women). MAIN OUTCOME MEASURES: Incident AF. RESULTS: AF developed in 698 participants (13.1%) a median of 12 years after pulse pressure assessment. Cumulative 20-year AF incidence rates were 5.6% for pulse pressure of 40 mm Hg or less (25th percentile) and 23.3% for pulse pressure greater than 61 mm Hg (75th percentile). In models adjusted for age, sex, baseline and time

JAMA2007

697. Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation

Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation Article Text Therapeutics Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you

Evidence-Based Medicine (Requires free registration)2007

698. Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation

Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation Article Text Therapeutics Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2007

699. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis

Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis Nasr I A, Bouzamondo A, Hulot J S, Dubourg O, Le Heuzey J Y, Lechat P CRD summary This review concluded that beta-blocker administration appears to effectively reduce the incidence (...) of atrial fibrillation in patients with systolic heart failure. The authors’ conclusions appear supported by the evidence presented, but without details of the methodological quality of the studies it is difficult to assess their reliability. Authors' objectives To evaluate the effect of beta-blocker administration on the incidence of atrial fibrillation (AF) in patients with congestive heart failure (HF). Searching PubMed and the Cochrane CENTRAL Register were searched; the search terms were reported. Only studies

DARE.2007

700. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation

Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Buckley M S, Nolan P E, Slack M K, Tisdale J E, Hilleman D E, Copeland J G CRD summary This review concluded that total (...) amiodarone doses of 3,000 mg or higher may be more effective than lower doses in reducing the rate of post-operative atrial fibrillation after cardiac surgery. Pre-operative initiation of amiodarone appears to be unnecessary. Given the potential weaknesses in the review methods and analyses, it is difficult to assess the robustness of the authors' conclusions. Authors' objectives To assess optimal dosing regimens of prophylactic amiodarone for reducing the incidence of atrial fibrillation (AF) after

DARE.2007